# Pharmacogenetic implementation plan for patients treated with depot antipsychotics - URL: https://alisanburak.com/en/wcp-2026-posterler/so149 - Language: en - Last updated: not specified - Page title: Pharmacogenetic implementation plan for patients treated with depot antipsychotics | WCP 2026 Summary > Pharmacogenetic testing and therapeutic drug monitoring were successfully integrated into routine psychiatric care in a program involving 540 patients receivin… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/so149) Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun. SO149 Kısa Sözlü Poster SunumuPsikofarmakolojiGözlemsel uygulama programı # Pharmacogenetic implementation plan for patients treated with depot antipsychotics PHARMACOGENETIC IMPLEMENTATION PLAN IN PATIENTS TREATED WITH DEPOT ANTIPSYCHOTICS Sunan: Olalla M. Maroñas Amigo Ülke: Spain Oturum: 2840 - PARALLEL SHORT ORAL POSTER SESSIONS: NEUROSCIENCE & NEUROIMAGING - Part II Tarih: Thu, 24.09.2026 Pharmacogenetic testing and therapeutic drug monitoring were successfully integrated into routine psychiatric care in a program involving 540 patients receiving long-acting injectable antipsychotics; 45% of patients had a non-normal CYP2D6 metabolizer phenotype. The study aimed to design and implement a pharmacogenetic (PGx) and pharmacokinetic testing program for patients receiving long-acting injectable (LAI) antipsychotics in the Galician Health Service. Between 2021 and October 2025, 540 patients were enrolled in the program; PGx testing and/or therapeutic drug monitoring (TDM) were requested according to predefined clinical indications, and the results were integrated into the electronic health record (IANUS). Genotyping was performed using real-time PCR with a panel covering CYP2D6, CYP3A4, and ABCB1, including CYP2D6 copy number variation, while plasma levels of aripiprazole, dehydroaripiprazole, risperidone, and paliperidone were measured using a validated UHPLC-MS/MS method. A non-normal CYP2D6 metabolizer phenotype was identified in 45% of patients: normal metabolizers accounted for 55.0%, intermediate metabolizers for 34.4%, poor metabolizers for 6.3%, and ultrarapid metabolizers for 4.3%. CYP3A4 *20/*22 variants were absent in 93.3% of patients, while ABCB1 T allele variants were detected in 10.5%. Most of the 333 patients with concomitant medication data were taking 1 to 6 medications (median 4); potential CYP2D6-mediated drug–gene interactions were identified in 8% of normal metabolizers, primarily due to fluoxetine. TDM comprised 350 measurements in 343 patients; the proportions below, within, and above the target range were 14.4%, 62.6%, and 21.6% for paliperidone; 19.5%, 51.7%, and 27.6% for risperidone; and 21.0%, 66.9%, and 8.9% for aripiprazole. Program effectiveness indicators were reported as clinical follow-up in 54.6%, switching from oral treatment to an LAI in 38.5%, and suspected adverse drug reactions in 6.9%. The results show that PGx and TDM can feasibly be integrated into routine psychiatric care through structured workflows, trained staff, and electronic health record integration; the next step is to prospectively evaluate PGx- and TDM-guided treatment and clinical outcomes. [Orijinal postere git](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2005) Bu çalışmaya nasıl atıf yapılır? APA 7: Amigo, O. M. M., et al. (2026, September 24). Pharmacogenetic implementation plan in patients treated with depot antipsychotics [Poster presentation]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2005 Vancouver: Amigo OMM, et al. Pharmacogenetic implementation plan in patients treated with depot antipsychotics [poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2005 Yazar adları ve başlık biçimi kongre sisteminden otomatik oluşturulmuştur; kullanmadan önce orijinal posterle karşılaştırın. ## Aynı konudan - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [Tüm WCP 2026 özetleri](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/so149 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim